Biotechnology
Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026
* Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on interim data from 10 enrolled patients * A manageable safety profile, with prolonged disease control and tumor recurrence inhibition observed in several patients SEONGNAM and SEOUL, South Korea, Ju...
2026-06-15 12:00
7236
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
SHANGHAI, June 12, 2026 /PRNewswire/ -- On May 29, 2026, Pacific Time, Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory study in the respiratory field, with the aim of developing innovative ther...
2026-06-12 14:59
8046
Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 11, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...
2026-06-12 09:19
8857
CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy. I. Trispecific Design Rationale and Di...
2026-06-11 14:20
7325
Caliway Unveils Latest OI25 Animal Study Data for CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies at ADA 2026, Demonstrating Dual Potential to Attenuate Post-Discontinuation Weight Regain and Improve Metabolic Health
Backed by International Authority — Caliway's latest preclinical data on its proprietary localized fat reduction candidate, CBL-514, in combination with GLP–1R–based weight–loss therapies, were presented at the American Diabetes Association 2026 Scientific Sessions (ADA 2026). The findings were d...
2026-06-11 12:54
5020
Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 10, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...
2026-06-11 09:52
4481
HkeyBio Launches "NHP Fast-PoC" Program to Deliver Low-Cost Cyno PK/PD and Developability Data Amid Rising NHP Prices
The cost-effective platform delivers rapid pharmacological validation data in cynomolgus monkeys, helping biotech firms make confident R&D decisions before committing to full-scale IND studies. BOSTON and SUZHOU, China, June 10, 2026 /PRNewswire/ -- HkeyBio, a specialized preclinical CRO focused...
2026-06-10 21:16
7737
NOROO Holdings Advances Commercialization of Bio-Based 3-HP Through Major Korean Government Initiative
* Selected as the lead organization for a major government-backed initiative to accelerate commercialization of bio-based 3-HP through pilot-scale investments. * Establishing an integrated R&D value chain spanning feedstock development, production, and downstream applications through collabor...
2026-06-10 21:00
6148
UndoAge and Novonesis Forge Strategic Partnership to Drive High-Quality Development of China's Probiotic Industry
Beijing, June 10, 2026 /PRNewswire/ -- UndoAge and Novonesis, a global biosolutions company backed by Novo Holdings, signed a Memorandum of Understanding (MOU) in Beijingon June 9. The partnership will deepen collaboration in probiotics and microbiome health, with a focus on high-growth consumer...
2026-06-10 20:38
4068
Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 10, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...
2026-06-10 12:06
6011
PromptBio Launched All-New Agentic AI Platform For Life Sciences, Turning Scientific Intent Into Executable Experiments
The PromptBio Platform combines conversational AI with multi-agent orchestration to accelerate discovery from hypotheses to insights PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- PromptBio, a California-based leader in AI for life sciences, announced the launch of the All-New PromptBio Platfo...
2026-06-09 22:07
9270
SK bioscience Joins Forces with Global Institutions to Advance Rotavirus Vaccine Development
* SK bioscience licenses vaccine technology from the U.S. Centers for Disease Control and Prevention * SK bioscience is jointly investing with the RIGHT Foundation to drive process development that enhances both efficacy and productivity * "We are committed to improving public health through...
2026-06-09 20:00
3736
WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
DUNDALK, Ireland, June 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Ireland site won the "Overall Excellence in Life Sciences" award, the highest recognition at the 2026 Life Scie...
2026-06-08 16:09
4401
OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
SHANGHAI, June 7, 2026 /PRNewswire/ -- OriCell Therapeutics Holdings Limited ( The "Company" or "Oricell") ,announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China's National Medical Products Administration (NMPA) to proceed into a confir...
2026-06-08 08:08
4412
Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass and preventing post-treatment weight rebound. NEW ORLEANS, June 5, 2026 /PRNewswire/ -- Ractigen Therapeutics, a ...
2026-06-06 08:30
7290
SynbioTech Launches SYNMUE™ Targeting Immunosenescence, to Showcase at Probiota Americas 2026 in Vancouver
Clinical Study Showed Up to 48% Natural Killer Cell Increase with probiotic strain LP281 VANCOUVER, BC, June 5, 2026 /PRNewswire/ -- Synbio Tech Inc. (SynbioTech), a global leader in biotechnology solutions, today announced the launch of SYNMUE™, a clinically validated probiotic featuringLactipl...
2026-06-06 03:15
9894
Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, mor...
2026-06-05 22:00
12156
Mabwell's 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative antibody drug 9MW5211 has received approval from the National Medical Products Adminis...
2026-06-05 11:30
5553
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Once operational, the facil...
2026-06-05 10:45
10187
Natural Field Announces New Cartilage Health Research Findings Ahead of CPHI China 2026
XI'AN, China, June 4, 2026 /PRNewswire/ -- Natural Field recently completed a Phase I scientific evaluation study on joint health functionality. The results demonstrated that glucosamine-chondroitin co-loading liposomes exhibited significant activity in a cartilage injury repair model, providing ...
2026-06-04 23:00
4977
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 292 media titles]
2026-09-24 10:30
CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 291 media titles]
2026-09-22 18:37
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 279 media titles]
2026-09-23 09:00
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 275 media titles]
2026-09-25 14:45
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 275 media titles]
2026-09-21 08:00Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
10865
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
10825
Dreame Technology Opens New Flagship Store at Suntec City, Expanding Smart Living Experience in Singapore
2026-09-25 18:33
9750
